CRIS Current Research Information System

AMBROSINI, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.182
EU - Europa 5.612
AS - Asia 3.308
AF - Africa 353
SA - Sud America 17
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 17.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.160
GB - Regno Unito 1.924
VN - Vietnam 1.159
CN - Cina 1.116
DE - Germania 773
IT - Italia 714
SE - Svezia 632
SG - Singapore 571
UA - Ucraina 346
IN - India 338
IE - Irlanda 256
FR - Francia 232
RU - Federazione Russa 225
ZA - Sudafrica 128
EE - Estonia 119
CH - Svizzera 106
TG - Togo 97
FI - Finlandia 67
CI - Costa d'Avorio 61
JO - Giordania 47
BG - Bulgaria 46
NG - Nigeria 37
BE - Belgio 35
AT - Austria 29
GR - Grecia 24
SC - Seychelles 24
IR - Iran 22
ES - Italia 18
TR - Turchia 18
NL - Olanda 17
HR - Croazia 13
CA - Canada 11
HK - Hong Kong 9
BR - Brasile 8
JP - Giappone 8
LB - Libano 8
MX - Messico 7
PL - Polonia 7
AU - Australia 6
CZ - Repubblica Ceca 6
DK - Danimarca 4
RO - Romania 4
BJ - Benin 3
CO - Colombia 3
MD - Moldavia 3
SM - San Marino 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AR - Argentina 2
CL - Cile 2
EU - Europa 2
HU - Ungheria 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
PK - Pakistan 2
PT - Portogallo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
ID - Indonesia 1
JM - Giamaica 1
KR - Corea 1
LU - Lussemburgo 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TW - Taiwan 1
Totale 17.482
Salva come PNG Salva come JPEG
Città #
Southend 1.798
Fairfield 1.160
Chandler 735
Ashburn 611
Woodbridge 543
Houston 505
Seattle 503
Wilmington 476
Singapore 475
Princeton 407
Cambridge 384
Dong Ket 384
Ann Arbor 276
Dublin 256
Jacksonville 216
Nanjing 165
Westminster 160
Bologna 148
Padova 144
Berlin 111
Lomé 97
Bern 96
Jinan 88
Santa Clara 81
Shenyang 80
Beijing 79
Saint Petersburg 76
New York 71
Hebei 66
Redmond 62
Abidjan 61
Helsinki 58
Medford 56
Mülheim 51
Changsha 50
San Diego 50
Nanchang 48
Amman 47
Boardman 45
Milan 45
Turin 45
Bremen 44
Guangzhou 40
Sofia 39
Tianjin 39
Abeokuta 35
Dearborn 33
Jiaxing 31
Redwood City 30
Los Angeles 29
Des Moines 28
Zhengzhou 27
Brussels 26
Florence 26
Falls Church 24
Haikou 23
Hangzhou 23
Mahé 23
Shanghai 23
Vienna 21
Kuban 20
Olalla 20
Norwalk 19
Taizhou 18
Kunming 17
Ningbo 15
Taiyuan 15
San Venanzo 13
Lanzhou 12
Mountain View 12
Paris 12
Verona 12
Bühl 10
Costa Mesa 10
Fuzhou 10
Istanbul 10
Rome 10
Shenzhen 10
Wuhan 10
Calderara di Reno 9
Chicago 9
Frankfurt Am Main 9
London 9
Frankfurt am Main 8
Hefei 8
Lappeenranta 8
Breda 7
Buffalo 7
Genzano Di Roma 7
Naples 7
São Paulo 7
Ozzano dell'Emilia 6
Pune 6
Wenzhou 6
Alvaro Obregon 5
Benevento 5
Chengdu 5
Foshan 5
Fremont 5
Hyderabad 5
Totale 11.771
Salva come PNG Salva come JPEG
Nome #
(18)F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. 181
18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. 177
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. 169
68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. 165
18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients. 165
Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study 163
A [68Ga]Ga-DOTANOC PET/CT radiomic model for non-invasive prediction of tumour grade in pancreatic neuroendocrine tumours 163
18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy 162
Comparing PET-derived semiquantitative parameters and radiomic features in discriminating G1 and G2 primary pancreatic neuroendocrine tumours in 68Ga-DOTANOC PET/CT 162
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 161
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 159
18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin 157
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. 157
Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy 157
18F-FDG PET/CT detects systemic involvement in Sarcoidosis 154
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. 153
68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: Results of a prospective study on 50 patients 153
68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma 150
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 149
F-18 FDG PET/CT detects muscle involvement in Erdheim-Chester disease 146
18F-FDG PET/CT for the Assessment of Disease Extension and Activity in Patients With Sarcoidosis: Results of a Preliminary Prospective Study 144
Is surgery the best treatment for sporadic small (≤2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience 141
68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. 139
Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. 138
The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. 138
68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. 138
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. 134
Radiomic analysis performed on 68Ga-DOTANOC PET/CT allows discriminating primary pancreatic neuroendocrine tumour grading 133
Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. 132
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 131
Evaluation of unusual neuroendocrine tumours by means of (68)Ga-DOTA-NOC PET. 129
18f-fdg pet/ct for restaging gastric cancer after surgical resection 127
68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. 127
Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). 126
(18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. 125
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 120
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 120
Cardiac FDG PET/CT to Assess the Culprit Lesion during Acute Infarction 117
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 116
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results 116
Colon Sarcoidosis Mimicking Cancer at 18F-FDG PET/CT 116
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. 115
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 115
A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience 115
Radiomic analysis could allow detecting misassigned bioptic grading when discriminating G1 and G2 primary pancreatic neuroendocrine tumours imaged with 68Ga-DOTANOC PET/CT 114
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. 113
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. 112
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 112
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. 112
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 111
A new dimension of FDG-PET interpretation: assessment of tumor biology. 111
Analisi in vitro ed in vivo dell'attività anti-tumorale dopo inibizione specifica di MYCN mediante PNA-NLS anti-gene nel rabdomiosarcoma umano 110
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 110
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma 110
(68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. 110
Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. 109
18F-FDG PET/CT impact on testicular tumours clinical management 109
Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. 108
Incidental finding of an (11)C-choline PET-positive solitary plasmacytoma lesion. 107
Comparison of Different Positron Emission Tomography Tracers in Patients with Recurrent Medullary Thyroid Carcinoma: Our Experience and a Review of the Literature 106
Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma 106
Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma 105
Is there an ideal diagnostic algorithm in solitary pulmonary nodules? 105
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. 105
Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF 105
Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Review 105
Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis 105
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 104
Small animal PET for the evaluation of an animal model of genital infection 104
Merkel cell carcinoma: a prompt diagnosis to increase survival 104
Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis 104
Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours 101
FDG small animal PET permits early detection of malignant cells in a xenograft murine model. 101
Ga-68-DOTA-peptides versus F-18-DOPA PET for the assessment of NET patients 100
68Ga-DOTA-NOC PET and CT retrospective analysis for neuroendocrine bone metastasis detection 100
Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? 99
G1/G2 discrimination of pNET with [68Ga]Ga-DOTANOC PET/CT quantitative parameters: is it feasible? 99
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. 98
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis 97
Performance evaluation of a small animal PET scanner. Spatial resolution characterization using F-18 and C-11. 97
Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling 95
Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review 94
Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report 94
Preliminary results of the Italian FOLCETUX study: early evaluation of treatment response with 18FDG PET in gastric or gastroesophageal junction adenocarcinoma. 93
Neuroendocrine Tumours Pictorial Atlas 93
Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma 93
Molecular Imaging with Small Animal PET/CT 92
Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice 92
Pitfalls in oncology: Osteoblastic response mimicking bone progression during ceritinib treatment in ALK-rearranged NSCLC 92
Small animal PET in oncology: the road from bench to bedside. 92
68Ga-DOTA-NOC and 18F-DOPA PET in the evaluation of patients with neuroendocrine tumours. 91
Positron-emission tomography in gynaecologic malignancies. 91
68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone level. 91
18f-FDG small animal PET for early detection of human anaplastic large cell lynphoma xenografts in immunocompromised mice 90
Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience 90
Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials 90
Neuroendocrine Tumours with Secondary Liver Lesions 88
68Ga-DOTA-peptides in the Diagnosis of NET 88
Lung cancer associated with cystic airspaces 88
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management 88
Totale 11.888
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.642
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.642
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.648 0 0 0 261 421 440 563 589 562 326 201 285
2020/20212.586 485 147 64 92 36 86 44 249 297 137 170 779
2021/20223.781 846 112 204 222 298 178 55 252 140 138 818 518
2022/20233.481 385 509 207 435 211 245 100 183 563 189 265 189
2023/2024885 96 159 40 77 72 167 53 56 34 61 35 35
2024/20251.286 144 648 350 144 0 0 0 0 0 0 0 0
Totale 17.891